Navigation Links
Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform
Date:3/30/2012

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced completion of an $11.8 million Series B financing.  New investors Redmile Group and Claremont Creek Ventures and private investors from Genalyte's Series A round participated in the Series B financing.  Genalyte intends to use the new funds primarily for commercialization of its Maverick™ platform and its highly multiplexed panels for autoimmune and immunoassay applications.

Genalyte has pioneered an entirely new approach to immunodetection using silicon chip manufacturing methods.  The Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies and antigens or hybridization of nucleic acids.  This technology eliminates the need for complex processing associated with current multiplexed testing, while leveraging the manufacturing advantages of silicon chips.  Genalyte is preparing to launch the Maverick platform this summer, initially addressing the autoimmunity research and testing markets.

"By applying advances in silicon photonics to the life sciences, we have been able to develop a completely new approach to biological detection that provides major advantages to researchers and, eventually, to clinicians," commented Genalyte CEO and founder Cary Gunn.  "Our initial funding enabled us to fully develop and refine the silicon photonics biosensor consumables that are the heart of the Maverick system, along with the instrument itself and our initial multiplexed immunology panels.  This new financing provides us with the resources to launch the platform in the coming months and to begin to populate it with a wide variety of proprietary assays for multiple applications."

The Maverick platform runs scalable multiplexed assays using a silicon chip that contains arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample.
Assays do not require the washes, incubations, reagents or other processing steps typically associated with sample preparation.  The assays are therefore simple to use and rapid -- results are available in only 15 minutes, including just two minutes of hands-on time.  The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.

Dr. Gunn continued, "By using silicon-based technologies, we can provide customers with unprecedented system performance while leveraging the highly efficient production characteristic of traditional silicon chip manufacturing.  During our four years of development, we and our academic collaborators generated a large number of peer-reviewed studies that provide important validation for the superiority of our detection data and the breadth of applications that are possible.  We look forward to unveiling the Maverick platform at upcoming scientific meetings and to making this exciting new technology available to researchers worldwide."

Genalyte will be discussing the Maverick platform at several upcoming scientific meetings, including:

Europt(r)ode XI, Optical Chemical Sensors and Biosensors, Barcelona, Spain, April 1-4, 2012, www.europtrodexi.eu/Industrial-session.html

Immunology 2012™, the 99th Meeting of the American Association of Immunologists, Boston, MA, May 4-8, 2012, http://immunology2012.org

8th International Congress on Autoimmunity, Granada, Spain, May 9-13, 2012,  www2.kenes.com/autoimmunity/pages/home.aspx

For more information about Genalyte and the Maverick platform, visit www.genalyte.com.

About Genalyte 
Since 2007, Genalyte's mission has been to develop instrument systems, hardware, software and consumables making multiplex protein and nucleic acid testing from a single sample the standard in the research, life science and clinical diagnostic markets.  Genalyte's multiplexing platform incorporates the company's revolutionary Microring Sensor Technology™, a new approach to multiplexing that reduces or eliminates sample preparation, provides scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieves up to eight logs of dynamic range.  Genalyte is preparing to launch the Maverick™ platform, which uses this technology to run scalable multiplexed assays that do not require the washes, incubations or other processing steps associated with sample preparation.  The Maverick™ platform has a large dynamic range and excellent sensitivity. 

About Claremont Creek Ventures
Claremont Creek Ventures is a seed and early stage venture capital firm investing in digital healthcare, energy technology, payments/commerce, and online businesses.  Claremont Creek has $300 million in capital under management in two funds.  For more information, visit www.claremontcreek.com.Contacts:

 Genalyte, Inc.

Media: Martin Gleeson

BioCom Partners VP, Development & Applications

Barbara Lindheim +1 858 750-4470

+1 212 584-2276 x201 martin@genalyte.com

blindheim@biocompartners.com


'/>"/>
SOURCE Genalyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):